



1642
Docket No: L00461.70112.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED


NOV 21 2002

TECH CENTER 1600/2900

Applicant : Yuichi Obata
Serial No. : 09/835,992
Conf. No. : 6680
Filed : April 17, 2001
For : ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH
GASTRIC CANCER AND METHODS FOR DIAGNOSING AND
TREATING GASTRIC CANCER
Examiner : Anne L. Holleran
Art Unit : 1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 15th day of November, 2002.


June Watson

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

☒ Response to Further Restriction Requirement

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

No fee is required. If a fee is determined to be required, please charge the balance to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Yuichi Obata, Applicant

By:



John R. Van Amsterdam, Reg No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500
Attorneys for Applicant

Docket No. L00461.70112.US
Dated: November 15, 2002
x11/22/02x

658578.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 21 2002

Applicant : Yuichi Obata
Serial No. : 09/835,992
Conf. No. : 6680
Filed : April 17, 2001
For : ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH
GASTRIC CANCER AND METHODS FOR DIAGNOSING AND
TREATING GASTRIC CANCER
Examiner : Anne L. Holleran
Art Unit : 1642

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 15th day of November, 2002.


June Watson

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO FURTHER RESTRICTION REQUIREMENT

Sir:

In response to the Action mailed on October 22, 2002 requiring a further restriction requirement, Applicant elects Group I, claims 13-17, 31 and 32, with traverse, drawn to methods for determining gastric cancer or a related condition comprising assaying for an antibody that binds to sterol carrier protein-X/sterol carrier protein-2.

Remarks

Claims 13-17 and 31-32 as they relate to methods for assaying for an antibody that binds to sterol carrier protein-X/sterol carrier protein-2 are elected with traverse. Applicant traverses the election requirement because, while acknowledging that the two types of antibodies identified by the Examiner are different, Applicant does not believe that examination of both antibody types would entail a significant burden on the Examiner.